US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Missfresh Limited

1.00

+0.0000

Volume:- -

Turnover:- -

Market Cap:7.77M

PE:-0.03

High:1.00

Open:1.00

Low:1.00

Close:1.00

Loading ...

Overview Company News Filings

Generali Interested in Small U.S. Asset Managers, Milano Finanza Says, Citing Sources

BRIEF-Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

The ASX-listed Biotech set to unlock significant value

The Magnificent Seven have seen persistent selling from active funds – Citi

Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study

Press Release: Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

Press Release: Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies

PEYAX: A Large-Cap Value MF Worth Considering

Huafon MF's Subsidiaries to Payout 520 Million Yuan in Dividends

MT Newswires Live

FEQIX: The Other Equity MF In My Mom's IRA - Sell Rating

BRIEF-Google Updates Gambling And Games Policy, Brazil

Incyte Gains 12.7% Year to Date: How Should You Play the Stock?

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

AT&T Signs Five-Year Deal to Leverage Nokia's Lightspan MF, Altiplano Platforms to Support Fiber Network

MT Newswires Live

MASSEY FERGUSON® 9S SERIES TRACTOR BRINGS EFFICIENCY AND DEPENDABILITY TO YOUR FARM

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MF/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"MF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MF\",,,,,undefined,":{"symbol":"MF","market":"US","secType":"STK","nameCN":"Missfresh Limited","latestPrice":1,"timestamp":1743624000000,"preClose":1,"halted":4,"volume":0,"delay":0,"floatShares":5586728,"shares":7772983,"eps":-28.707302,"marketStatus":"Delisted","change":0,"latestTime":"04-02 16:00:00 EDT","open":1,"high":1,"low":1,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-28.707302,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743667200000},"marketStatusCode":5,"adr":0,"adrRate":90,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":1,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MF\",,,,,undefined,":{"symbol":"MF","floatShares":5586728,"roa":"-44.95%","roe":"-2003.66%","lyrEps":-28.663709,"shares":7772983,"dividePrice":0,"high":1,"amplitude":0,"preClose":1,"low":1,"week52Low":0.4111,"pbRate":"-0.04","psRate":"0.02","week52High":3.28,"institutionHeld":0,"latestPrice":1,"eps":-28.707302,"divideRate":0,"volume":0,"delay":0,"ttmEps":-28.707302,"open":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MF\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2489406427","title":"Generali Interested in Small U.S. Asset Managers, Milano Finanza Says, Citing Sources","url":"https://stock-news.laohu8.com/highlight/detail?id=2489406427","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489406427?lang=en_us&edition=fundamental","pubTime":"2024-12-06 17:22","pubTimestamp":1733476920,"startTime":"0","endTime":"0","summary":"--Italian insurer Generali is considering two or three small U.S. asset managers as takeover targets, MF-Milano Finanza reports, citing unnamed sources.--Generali is evaluating businesses that are smaller than Conning, the U.S. investment manager whose acquisition it completed in April, according to MF . New York-based Mgg Investment Group was named as one of the potential targets.-- Woody Bradford, who leads the Generali Investments,  is personally involved in the process, MF reports.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4113","BK4563","MF","BK4526"],"gpt_icon":0},{"id":"2489566274","title":"BRIEF-Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489566274","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489566274?lang=en_us&edition=fundamental","pubTime":"2024-12-05 21:11","pubTimestamp":1733404317,"startTime":"0","endTime":"0","summary":"Dec 5 (Reuters) - Ryvu Therapeutics SA   :   * RYVU THERAPEUTICS ANNOUNCES DOSING OF THE FIRST PATIENT IN THE POTAMI-61 PHASE II STUDY OF RVU120 FOR THE TREATMENT OF PATIENTS WITH MYELOFIBROSIS (MF)Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4113","BK4563","MF","LENZ","BK4526"],"gpt_icon":0},{"id":"2488916961","title":"Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2488916961","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488916961?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:00","pubTimestamp":1733227200,"startTime":"0","endTime":"0","summary":"Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis. Takeda to receive exclusive global license in all territories outside of mainland China, Hong Kong and Macau. Transaction builds upon Takeda’s legacy in the treatment of hematologic cancers and advances company’s global oncology strategy. OSAKA, Japan & CAMBRIDGE, Mass., December 03, 2024----Takeda  today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc.  to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.\"We are excited to partner with Takeda, whose global reach and expertise in oncology and hematology will help unlock elritercept’s potential for patients with MDS and MF,\" said Jasbir S. Seehra, Ph.D., Chair and Chief Executive Officer at Keros Therapeutics. \"With a differenti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Mtrw27NZWWLQ31pFftNF8Q--~B/aD0yNjY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ab83e63c40e11825b14fac38a19f4ad0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Mtrw27NZWWLQ31pFftNF8Q--~B/aD0yNjY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ab83e63c40e11825b14fac38a19f4ad0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/takeda-strengthens-oncology-pipeline-elritercept-120000571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4563","TAK","BK4113","BK4539","BK4526","LENZ","BK4007","MF","BK4139"],"gpt_icon":0},{"id":"2486593558","title":"The ASX-listed Biotech set to unlock significant value","url":"https://stock-news.laohu8.com/highlight/detail?id=2486593558","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486593558?lang=en_us&edition=fundamental","pubTime":"2024-11-27 07:50","pubTimestamp":1732665047,"startTime":"0","endTime":"0","summary":"Syntara is not your typical ASX-listed biotech. This small company with a market cap of just ~A$60 million is equipped with a world class in-house drug discovery engine that has produced five lead candidates for disease with high unmet need with a shareholder base of mostly institutional investors including Australian and US specialist healthcare funds.Focused on rare and underserved diseases like myelofibrosis , Syntara is advancing three promising compounds into Phase 2 clinical trials, supported largely by non-dilutive funding. With an estimated ~US$3 billion market opportunity for MF in the U.S. alone, key clinical milestones on the horizon, a highly differentiated product pipeline, a potential accelerated path to market, and with comparable acquisitions in MF indicating ~50x upside from current levels, Syntara is positioned as a biotech company with significant upside potential and one to watch closely.Syntara has now been listed for 23-years on the ASX. At KP Rx we focus on ident","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-asx-listed-biotech-set-to-unlock-significant-value","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-asx-listed-biotech-set-to-unlock-significant-value","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["AML.AU","MF","BK7504","BK4093","BK7094","BK7057","ASH.AU","BK4563","BK4585","ASH","BK4113","BMT.AU","BK4588","BK4539","CF","LU2463526074.USD","BK4109","TSS","BK7095","BK4526"],"gpt_icon":0},{"id":"2486058302","title":"The Magnificent Seven have seen persistent selling from active funds – Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2486058302","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486058302?lang=en_us&edition=fundamental","pubTime":"2024-11-26 01:34","pubTimestamp":1732556080,"startTime":"0","endTime":"0","summary":"5./15 WEST Most “Magnificent Seven” stocks have seen selling from active ETFs, mutual funds and hedge funds due to profit taking, concentration, and risk management, according to Citi Research. Accord","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1142745464/image_1142745464.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1142745464/image_1142745464.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4330984-the-magnificent-seven-have-seen-persistent-selling-from-active-funds-citi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["3NVD.UK","LU1803068623.USD","SG9999001424.SGD","NVDY","SG9999015952.SGD","SNVD.UK","00201","LU0006306889.USD","LU1323610961.USD","META","TSLA","MF","NVDX","LU0320765489.SGD","NVDS.UK","NVDA","SG9999004303.SGD","NVD3.UK","GOOGL","LU0353189763.USD","IE00B3SWFQ91.USD","NVDU","AAPL","LU2264538146.SGD","MSFT","GOOG","NVD2.UK","LU2298321311.HKD","2NVD.UK","LU0784385170.HKD","BK4598","NVD","FDN","LU0472753341.HKD","LU2602419157.SGD","LU0784383803.USD","LU1670711123.USD","MAGS","LU1699723380.USD","LU0157215616.USD","LU2362541273.HKD","LU1935042488.USD","LU2242649171.HKD","LU0426417589.USD","LU0823434740.USD","LU1720051108.HKD","NVDD","NVDS"],"gpt_icon":1},{"id":"2484903667","title":"Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903667","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484903667?lang=en_us&edition=fundamental","pubTime":"2024-11-20 02:54","pubTimestamp":1732042440,"startTime":"0","endTime":"0","summary":"Incyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2  in chronic spontaneous urticaria .Consequently, shares of Incyte were down 9% on Nov. 18 in after-market trading.Shares of Incyte have risen 5.4% year to date against the industry’s 11.1% decline.Incyte announced that it will pause enrollment in the ongoing phase II study of MRGPRX2 in CSU due to certain in vivo preclinical toxicology findings.The data was also shared with the FDA. The company is now working closely with the FDA to determine the next steps.Additionally, data from the phase II study evaluating MRGPRX4 in cholestatic pruritus does not support further development.IMCR’s earnings beat estimates in two of the trailing four quarters and missed the same in the other two, the average surprise being 25.57%.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incyte-pauses-enrollment-chronic-spontaneous-185400622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4563","BK4505","IMCR","BK4526","BK4532","CSTL","BK4585","GSK.UK","BK4007","BK4588","INCY","MF","BK4196","LU1829250122.USD","BK4539","GSK","BK4550","BK4113","BK4139"],"gpt_icon":0},{"id":"2482770925","title":"Press Release: Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482770925","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482770925?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:00","pubTimestamp":1731416400,"startTime":"0","endTime":"0","summary":"-- Completed a successful end of Phase 2 meeting with the FDA for bitopertin. in erythropoietic protoporphyria , reaching alignment on all. proposed study parameters with the potential for accelerated approval. -- Presented proof-of-mechanism data for Phase 1b trial of DISC-0974 in. anemia at the American Society of Nephrology  Kidney Week 2024. \"This is an exciting time for Disc as we have made significant progress in advancing our pipeline in recent months and remain keenly focused on execution as we prepare for multiple upcoming catalysts. We now have clarity on the path forward for bitopertin in EPP, with the potential for accelerated approval, and added to the data set supporting the potential of DISC-0974 in treating anemias of inflammation with positive SAD data in NDD-CKD,\" said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc. \"Additionally, with the recent completion of a debt financing with Hercules Capital, we have further solidified our strong financ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ASH","BK4582","IBD","LU2463526074.USD","IRON","EPP","BK4109","BK4526","BK4563","BK4113","BK4539","BK4089","MF","TSAT"],"gpt_icon":0},{"id":"2481108335","title":"Press Release: Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2481108335","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481108335?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:30","pubTimestamp":1731072600,"startTime":"0","endTime":"0","summary":"-- Facility significantly increases future financial and operational. -- Up to $200M available, with $30 million drawn at close and additional $80. million available at Disc's sole discretion through second-half 2026. recently announced potential accelerated approval pathway for bitopertin. \"Hercules is pleased to partner with Disc in the further development of their hematology pipeline,\" said Bryan Jadot, Senior Managing Director and Group Head at Hercules Capital. \"We are committed to financing promising life sciences companies to help them achieve their ambitious goals, and we are excited to collaborate with the Disc team ahead of numerous milestones and support them in their next phase of growth.\". The loan facility consists of up to four tranches, three of which can be drawn at Disc's option and each maturing in November 2029. The loan facility provides for at least 48-months of interest-only at close, which interest-only period can be extended up to 60 months upon satisfaction of","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4582","BK4113","IRON","BK4526","BK4139","BK4563","BK4539","BK4135","EPP","MF","HTGC"],"gpt_icon":0},{"id":"2481903507","title":"Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2481903507","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481903507?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:00","pubTimestamp":1730980800,"startTime":"0","endTime":"0","summary":"Achieved $28.2 million in RYTELO  net product revenue in first full quarter of sales. Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt. FOSTER CITY, Calif., November 07, 2024----Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2024 and recent business highlights.Strong execution in the first full quarter of U.S. launch, with net product revenue for RYTELO  of $28.2 million in the third quarter of 2024.New data to be presented at upcoming American Society for Hematology  Annua","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zZLo_DXqApn6_1miYjGswg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/42a99b4bc39a17084482402aa4c47f6e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zZLo_DXqApn6_1miYjGswg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/42a99b4bc39a17084482402aa4c47f6e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corporation-reports-third-quarter-120000278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4139","BK4109","ASH","CHMP","LU2463526074.USD","BK4097","GERN","BK4215","BK4563","BK4113","BK4588","BK4526","MAA","OS","BK4087","BK4585","MF"],"gpt_icon":0},{"id":"2481507387","title":"Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2481507387","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481507387?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:00","pubTimestamp":1730815200,"startTime":"0","endTime":"0","summary":"Oral presentation of complete data from Phase 1b trial of DISC-0974 in anemia of myelofibrosis . Poster presentations across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indications. Management will host a conference call during the ASH meeting on Sunday, December 8 at 9:00pm EST / 6:00pm PST. “We’re delighted to be presenting such a robust set of data at ASH showcasing the significant progress we’ve made across our entire portfolio. At the meeting, we’ll be providing clinical updates on each of our core development programs, setting us up for the next stages of development in EPP, MF and polycythemia vera,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc.“In addition, we look forward to sharing translational data from preclinical studies in new indications such as anemia of inflammatory bowel disease  and sickle cell disease , providing further evide","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b6JAqo9YqmUciEIrq0MClw--~B/aD04NDc7dz0xNDg4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/12ec4b12ac10afa4786e3a477034ad5b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b6JAqo9YqmUciEIrq0MClw--~B/aD04NDc7dz0xNDg4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/12ec4b12ac10afa4786e3a477034ad5b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/disc-medicine-announces-multiple-presentations-140000277.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4117","AFG","IE00B64QTZ34.USD","BK4582","BK4526","RBC","BK4107","BK4109","IE00BLDYK493.USD","BK4161","BK4563","BK4113","ASH","LU2463526074.USD","EPP","BK4139","BK4539","MF","IRON","LU2065731478.USD"],"gpt_icon":0},{"id":"2481500300","title":"Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies","url":"https://stock-news.laohu8.com/highlight/detail?id=2481500300","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481500300?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:00","pubTimestamp":1730815200,"startTime":"0","endTime":"0","summary":"New analyses from the IMerge clinical trial suggest that imetelstat demonstrates clinical activity in patients with lower-risk MDS with transfusion-dependent anemia regardless of prior therapy. Early safety results from the dose escalation phase of the Phase 1 IMproveMF study suggest potential for the tolerability of combination therapy with imetelstat and ruxolitinib in a frontline myelofibrosis patient population. \"We look forward to collaborating with our trial investigators to present meaningful data updates across the imetelstat pipeline, which we believe continue to highlight telomerase inhibition as an important and powerful approach to treating myeloid hematologic malignancies,\" said Faye Feller, M.D., Executive Vice President, Chief Medical Officer of Geron.\"There are very few treatment options today for patients with lower-risk MDS who have symptomatic anemia and are transfusion dependent, which often results in patients having to cycle through available therapies. By pooling","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DLHd3qHzsaqeCVwhLXBbtw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d4ca3d56651526b3065af8a55d25dba1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DLHd3qHzsaqeCVwhLXBbtw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d4ca3d56651526b3065af8a55d25dba1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-announces-data-presented-upcoming-140000897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4109","BK4566","PRO","BK4139","BK4113","BK4207","IE00BLDYK493.USD","BK4539","BK4526","RBC","BK4161","LU2463526074.USD","GERN","MF","BK4585","LU2065731478.USD","TD","BK4023","BK4563","IE00B64QTZ34.USD","ASH"],"gpt_icon":0},{"id":"2475384496","title":"PEYAX: A Large-Cap Value MF Worth Considering","url":"https://stock-news.laohu8.com/highlight/detail?id=2475384496","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475384496?lang=en_us&edition=fundamental","pubTime":"2024-10-13 22:00","pubTimestamp":1728828000,"startTime":"0","endTime":"0","summary":"J Studios Introduction My recent article on the Fidelity Equity-Income Fund (FEQIX) gave that mutual fund a Sell rating, with the suggestion that the Putnam Large Cap Value Fund A (MUTF:PEYAX) was a","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1771879591/image_1771879591.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1771879591/image_1771879591.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4725644-peyax-a-large-cap-value-mf-worth-considering","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_fund","symbols":["BK4539","BK4563","BK4113","BK4526","MF"],"gpt_icon":0},{"id":"2472653004","title":"Huafon MF's Subsidiaries to Payout 520 Million Yuan in Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=2472653004","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472653004?lang=en_us&edition=fundamental","pubTime":"2024-10-03 12:31","pubTimestamp":1727929913,"startTime":"0","endTime":"0","summary":"Huafon Microfibre   or Huafon MF will distribute dividends of up to 520 million yuan to shareholders from its subsidiaries, according to a Monday filing on the Shenzhen Stock Exchange.The subsidiaries, Jiangsu Huafeng Superfiber Materials and Weifutong Technology, will pay 400 million yuan and 120 million yuan, respectively.The dividends are based on the Chinese specialized microfiber manufacturer's audited accumulated undistributed profits for 2023, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0220","300180","MF"],"gpt_icon":0},{"id":"2472395683","title":"FEQIX: The Other Equity MF In My Mom's IRA - Sell Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2472395683","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472395683?lang=en_us&edition=fundamental","pubTime":"2024-10-01 00:24","pubTimestamp":1727713440,"startTime":"0","endTime":"0","summary":"Paper Boat Creative Introduction With the passing of my father, I took over managing all the finances for my mom as her POA. Since that included her IRA, I decided to take a deep dive into the mutual funds my father had in","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/571606663/image_571606663.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/571606663/image_571606663.jpg"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4723267-feqix-the-other-equity-mf-in-my-moms-ira-sell-rating","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_fund","symbols":["EQR","MF"],"gpt_icon":0},{"id":"2470054414","title":"BRIEF-Google Updates Gambling And Games Policy, Brazil","url":"https://stock-news.laohu8.com/highlight/detail?id=2470054414","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470054414?lang=en_us&edition=fundamental","pubTime":"2024-09-28 04:41","pubTimestamp":1727469670,"startTime":"0","endTime":"0","summary":"Sept 27  - Alphabet Inc   :   * GOOGLE -UPDATE TO GOOGLE ADS GAMBLING AND GAMES POLICY, BRAZIL TO RUN ADS FOR ONLINE SPORTS BETTING/ ONLINE GAMBLING SERVICES AFTER SEPT 30   * GOOGLE -ADVERTISERS MUST DEMONSTRATE THAT THEY HAVE REQUESTED AUTHORIZATION TO OPERATE THESE SERVICES FROM THE BRAZILIAN MINISTRY OF FINANCE    * GOOGLE: GAMBLING AGGREGATORS OF ANY KIND WILL NO LONGER BE ALLOWED TO ADVERTISE IN BRAZIL AFTER SEPTEMBER 30Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3S45H60.SGD","LU0348723411.USD","IE00BJLML261.HKD","LU0068578508.USD","LU0006306889.USD","LU0130103400.USD","BK4554","IE00BZ1G4Q59.USD","IE00BFSS8Q28.SGD","MF","IE00B7KXQ091.USD","IE00BYQQ9H92.USD","LU0061475181.USD","LU0234572021.USD","IE00BK4W5L77.USD","IE00BKDWB100.SGD","LU0082616367.USD","LU0128525929.USD","LU0109391861.USD","IE0004445239.USD","BK4514","IE00B5TLWC47.USD","BK4113","IE00BN29S564.USD","LU0130102774.USD","BK4532","GOOGL","IE00B775H168.HKD","LU0130518102.USD","BK4548","GOOG","IE0034235303.USD","IE00B1XK9C88.USD","LU0061474705.USD","LU0433182093.SGD","BK4553","LU0061474960.USD","IE00BJTD4N35.SGD","BK4533","BK4539","IE00B1BXHZ80.USD","IE00BK4W5M84.HKD","LU0211327993.USD","IE0009356076.USD","IE00BKPKM429.USD","BK4534","LU0053666078.USD","BK4538","LU0130517989.USD","LU0289960550.SGD"],"gpt_icon":1},{"id":"2470218606","title":"Incyte Gains 12.7% Year to Date: How Should You Play the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2470218606","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470218606?lang=en_us&edition=fundamental","pubTime":"2024-09-26 01:58","pubTimestamp":1727287080,"startTime":"0","endTime":"0","summary":"Shares of Incyte INCY have risen 12.7% in the past six months against the industry’s decline of 0.5%. The stock has also outperformed the sector and the S&P 500 during this time frame.The outperformance can be attributed to positive data readouts and new drug approvals. Lead drug Jakafi  also maintains momentum.Incyte’s lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera  in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis , including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute graft-versus-host disease  in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older.Sales in all indications continue to be strong and should maintain momentum.While the uptake of recently approved drugs has been goo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4qYAeIby_0fxQYGokmloZw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7813b4a575be05490cc210e943a2c6f1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4qYAeIby_0fxQYGokmloZw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7813b4a575be05490cc210e943a2c6f1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incyte-gains-12-7-date-175800987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVS","BK4578","BK4139","BK4113","BK4588","BK4539","BK4526","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0211331839.USD","IE00BJT1NW94.SGD","BK4550","IE00B2B36J28.USD","GSK","GSK.UK","MF","BK4585","BK4007","IE0002141913.USD","LU1829250122.USD","INCY","BK4563","IE0009355771.USD","BK4532","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2465544390","title":"Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2465544390","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465544390?lang=en_us&edition=fundamental","pubTime":"2024-09-05 20:30","pubTimestamp":1725539400,"startTime":"0","endTime":"0","summary":"CRANFORD, N.J., Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc.   and Citius Oncology, Inc.  , today announced that LYMPHIR has been added to the NCCN Clinical Practice Guidelines in Oncology . LYMPHIR is included based on an NCCN Category 2A recommendation which indicates a uniform NCCN consensus that the drug is appropriate as an option for patients with Cutaneous T-cell Lymphoma .LYMPHIR , a novel immunotherapy for the treatment of relapsed or refractory CTCL after at least one prior systemic therapy, was recently approved by the U.S Food and Drug Administration . The approval of LYMPHIR is based on results from the Phase 3 Pivotal Study 302  of CTCL patients who had previously received at least one systemic treatment. LYMPHIR is the only CTCL therapy that targets the interleukin-2  receptor found on malignant T-cells and Tregs.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lyzveXqzu4d1PfNj1ia_vQ--~B/aD0yMDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b9fff1eac44814237bf8b5b5f3339441","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lyzveXqzu4d1PfNj1ia_vQ--~B/aD0yMDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b9fff1eac44814237bf8b5b5f3339441"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/citius-pharmaceuticals-inc-citius-oncology-123000058.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citius-pharmaceuticals-inc-citius-oncology-123000058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4007","BK4526","BK4585","BK4113","BK4563","BK4588","CLS","LU2346227817.USD","LU2125910500.SGD","NHLD","BK4145","CMS","LU2637428348.USD","MF","LU2045819591.USD","CTXR","BK4208"],"gpt_icon":0},{"id":"2464187094","title":"AT&T Signs Five-Year Deal to Leverage Nokia's Lightspan MF, Altiplano Platforms to Support Fiber Network","url":"https://stock-news.laohu8.com/highlight/detail?id=2464187094","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464187094?lang=en_us&edition=fundamental","pubTime":"2024-09-03 20:04","pubTimestamp":1725365055,"startTime":"0","endTime":"0","summary":"AT&T  has entered into a five-year agreement with Nokia  to deploy fiber access technology, Nokia said Tuesday.Under the deal, Nokia will provide its Lightspan MF and Altiplano platforms to support upgrades to AT&T's existing fiber network and future network expansions.Price: 19.85, Change: -0.05, Percent Change: -0.25","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LU0149725797.USD","IE00BMPRXR70.SGD","IE00BMPRXN33.USD","BK4020","LU1621767810.EUR","IE00BSNM7G36.USD","BK4547","BK4585","IE00BFXG1179.USD","BK4550","LU2384288077.EUR","MF","LU1571399168.USD","BK4515","LU1621768206.USD","LU1621768115.EUR","NOK","T","BK4115","BK4507","LU1621767737.EUR","BK4534"],"gpt_icon":0},{"id":"2462997190","title":"MASSEY FERGUSON® 9S SERIES TRACTOR BRINGS EFFICIENCY AND DEPENDABILITY TO YOUR FARM","url":"https://stock-news.laohu8.com/highlight/detail?id=2462997190","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462997190?lang=en_us&edition=fundamental","pubTime":"2024-08-26 20:35","pubTimestamp":1724675700,"startTime":"0","endTime":"0","summary":"MF 9S SERIES HELPS FARMERS WHO DEMAND MORE ACHIEVE A BETTER OVERALL COST OF OWNERSHIP. DULUTH, Ga., Aug. 26, 2024 /PRNewswire/ -- AGCO Corporation , a global leader in the design, manufacture, and distribution of agricultural machinery and precision ag technology, today announced the North American debut of the Massey Ferguson 9S Seriestractor. Designed with the farmer in mind, the MF 9S Series offers dependability and efficiency to help farmers achieve a lower overall cost of ownership. Massey Ferguson will showcase the MF 9S Series during the 2024 Farm Progress Showin Boone, Iowa, on August 27-29.\"This machine is an industry-leading planting, baling and tillage solution, designed by and for farmers,\" said Brad Arnold, Vice President of Massey Ferguson North America.\"Massey Ferguson designed this 9S Series to have optimal power so that farmers can get the job done right night or day. When you have a short window of time to reach maximum yield potential, working in a tractor that turns","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QXzvCmXmTOF7vm8EioMJrQ--~B/aD0yMTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c88878c5bee19f33b71ce1cbad7f15b3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QXzvCmXmTOF7vm8EioMJrQ--~B/aD0yMTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c88878c5bee19f33b71ce1cbad7f15b3"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/massey-ferguson-9s-series-tractor-123500554.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/massey-ferguson-9s-series-tractor-123500554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2211817866.USD","LU1917777945.USD","BK4526","LU1989763690.USD","FARM","BK4152","LU0471298777.SGD","BK4212","BK4563","BK4113","LU2023250843.SGD","LU1989763427.SGD","LU0385154629.USD","BK4539","AGCO","LU1974910355.USD","MF","LU2106854487.HKD","LU2023250504.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-10-17","symbol":"MF","defaultRemindTime":1666013400000,"type":"split","dateTimestamp":1665979200000,"forFactor":30,"toFactor":1,"ratio":30},{"market":"US","date":"2021-11-11","symbol":"MF","fiscalQuarterEnding":"2021/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1636606800000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2021-08-26","symbol":"MF","fiscalQuarterEnding":"2021/06","expectedEps":-2.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1629950400000,"reportTimeType":"post","actualEps":-5.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MF\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MF\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MF","date":"2023-11-16","current":-0.03539,"percent":0.648601,"low":-32.11263,"twenty":-1.865237,"median":-0.069098,"eighty":-0.028106,"high":-0.008193,"avg":-0.938264,"sd":2.296797,"marketCap":7384333},"quantilePoints":[{"date":"2021-06-25","current":-7.110902,"twenty":-32.106975,"median":-32.098493,"eighty":-17.105939,"marketCap":2274463661},{"date":"2021-07-02","current":-6.338927,"twenty":-22.103457,"median":-6.51424,"eighty":-6.371352,"marketCap":2022530316},{"date":"2021-07-09","current":-5.592526,"twenty":-6.992819,"median":-6.372013,"eighty":-5.926166,"marketCap":1782369560},{"date":"2021-07-16","current":-5.984077,"twenty":-6.517989,"median":-6.0717,"eighty":-5.522099,"marketCap":1907158976},{"date":"2021-07-23","current":-4.944161,"twenty":-6.481456,"median":-5.907476,"eighty":-5.522099,"marketCap":1575172037},{"date":"2021-07-30","current":-4.118662,"twenty":-6.373995,"median":-5.860853,"eighty":-5.032259,"marketCap":1316175139},{"date":"2021-08-06","current":-3.651632,"twenty":-6.362753,"median":-5.549376,"eighty":-4.15531,"marketCap":1163131522},{"date":"2021-08-13","current":-3.545136,"twenty":-6.285482,"median":-5.501154,"eighty":-3.834435,"marketCap":1130168282},{"date":"2021-08-20","current":-3.298913,"twenty":-6.054175,"median":-5.164407,"eighty":-3.617928,"marketCap":1047760174},{"date":"2021-08-27","current":-2.247676,"twenty":-5.971821,"median":-4.231883,"eighty":-3.568741,"marketCap":1097205034},{"date":"2021-09-03","current":-2.06394,"twenty":-5.916667,"median":-4.129113,"eighty":-3.426663,"marketCap":1010087896},{"date":"2021-09-10","current":-2.084402,"twenty":-5.892157,"median":-3.92974,"eighty":-3.298913,"marketCap":1021860486},{"date":"2021-09-17","current":-2.033597,"twenty":-5.889782,"median":-3.772314,"eighty":-2.118927,"marketCap":993606276},{"date":"2021-09-24","current":-2.091421,"twenty":-5.860853,"median":-3.625571,"eighty":-2.091421,"marketCap":1021860486},{"date":"2021-10-01","current":-2.008209,"twenty":-5.592526,"median":-3.584663,"eighty":-2.084402,"marketCap":984188209},{"date":"2021-10-08","current":-1.920987,"twenty":-5.555677,"median":-3.565065,"eighty":-2.049887,"marketCap":941806901},{"date":"2021-10-15","current":-1.827187,"twenty":-5.543074,"median":-3.490033,"eighty":-2.028961,"marketCap":897071071},{"date":"2021-10-22","current":-1.798685,"twenty":-5.516855,"median":-3.34385,"eighty":-2.008209,"marketCap":890007519},{"date":"2021-10-29","current":-1.885702,"twenty":-5.501154,"median":-3.29115,"eighty":-1.950409,"marketCap":930034311},{"date":"2021-11-05","current":-1.893294,"twenty":-5.384903,"median":-2.15964,"eighty":-1.927796,"marketCap":934743349},{"date":"2021-11-12","current":-1.893111,"twenty":-5.384653,"median":-2.115775,"eighty":-1.926255,"marketCap":1083077937},{"date":"2021-11-19","current":-1.870877,"twenty":-4.944161,"median":-2.102864,"eighty":-1.907244,"marketCap":1068950831},{"date":"2021-11-26","current":-2.164917,"twenty":-4.600679,"median":-2.092748,"eighty":-1.910043,"marketCap":1236121554},{"date":"2021-12-03","current":-1.847004,"twenty":-4.288468,"median":-2.091421,"eighty":-1.910043,"marketCap":1057178241},{"date":"2021-12-10","current":-1.902408,"twenty":-4.221007,"median":-2.08155,"eighty":-1.900585,"marketCap":1090141481},{"date":"2021-12-17","current":-1.809835,"twenty":-4.15531,"median":-2.065507,"eighty":-1.892014,"marketCap":1035987591},{"date":"2021-12-23","current":-1.668547,"twenty":-4.127023,"median":-2.061006,"eighty":-1.877223,"marketCap":955933999},{"date":"2021-12-31","current":-2.053249,"twenty":-4.061267,"median":-2.053333,"eighty":-1.865237,"marketCap":1179613142},{"date":"2022-01-07","current":-1.921377,"twenty":-3.911087,"median":-2.049887,"eighty":-1.870717,"marketCap":1099559557},{"date":"2022-01-14","current":-1.803334,"twenty":-3.834945,"median":-2.033783,"eighty":-1.865237,"marketCap":1035987591},{"date":"2022-01-21","current":-1.312737,"twenty":-3.809281,"median":-2.02988,"eighty":-1.849351,"marketCap":755800036},{"date":"2022-01-28","current":-1.140833,"twenty":-3.724041,"median":-2.024208,"eighty":-1.816776,"marketCap":654555793},{"date":"2022-02-04","current":-1.255738,"twenty":-3.646303,"median":-2.012315,"eighty":-1.801982,"marketCap":720482273},{"date":"2022-02-11","current":-1.254691,"twenty":-3.628119,"median":-1.999947,"eighty":-1.777804,"marketCap":720482273},{"date":"2022-02-18","current":-1.114148,"twenty":-3.606924,"median":-1.961463,"eighty":-1.755207,"marketCap":642783203},{"date":"2022-02-25","current":-0.774362,"twenty":-3.595381,"median":-1.947993,"eighty":-1.721983,"marketCap":447358278},{"date":"2022-03-04","current":-0.827555,"twenty":-3.583604,"median":-1.938892,"eighty":-1.663136,"marketCap":477966995},{"date":"2022-03-11","current":-0.654366,"twenty":-3.576713,"median":-1.927974,"eighty":-1.510894,"marketCap":376722760},{"date":"2022-03-18","current":-0.656616,"twenty":-3.565676,"median":-1.926255,"eighty":-1.319719,"marketCap":376722760},{"date":"2022-03-25","current":-0.603653,"twenty":-3.560264,"median":-1.922921,"eighty":-1.272248,"marketCap":346114035},{"date":"2022-04-01","current":-0.422795,"twenty":-3.534115,"median":-1.914317,"eighty":-1.239112,"marketCap":242515270},{"date":"2022-04-08","current":-0.574772,"twenty":-3.47419,"median":-1.908994,"eighty":-1.204604,"marketCap":329632415},{"date":"2022-04-14","current":-0.452551,"twenty":-3.41082,"median":-1.905066,"eighty":-1.198285,"marketCap":258996897},{"date":"2022-04-22","current":-0.388816,"twenty":-3.3472,"median":-1.902408,"eighty":-1.093833,"marketCap":218263743},{"date":"2022-04-29","current":-0.21999,"twenty":-3.3405,"median":-1.893203,"eighty":-0.827555,"marketCap":121493086},{"date":"2022-05-06","current":-0.12872,"twenty":-3.298913,"median":-1.887625,"eighty":-0.801811,"marketCap":70470693},{"date":"2022-05-13","current":-0.126121,"twenty":-3.29115,"median":-1.876165,"eighty":-0.773724,"marketCap":67810091},{"date":"2022-05-20","current":-0.099135,"twenty":-2.247676,"median":-1.857377,"eighty":-0.656616,"marketCap":54059709},{"date":"2022-05-27","current":-0.067857,"twenty":-2.188119,"median":-1.849938,"eighty":-0.616576,"marketCap":36965915},{"date":"2022-06-03","current":-0.107464,"twenty":-2.173465,"median":-1.837741,"eighty":-0.602219,"marketCap":58886472},{"date":"2022-06-10","current":-0.123657,"twenty":-2.165894,"median":-1.809835,"eighty":-0.571443,"marketCap":67268553},{"date":"2022-06-17","current":-0.103563,"twenty":-2.152566,"median":-1.805486,"eighty":-0.521169,"marketCap":56272961},{"date":"2022-06-24","current":-0.117384,"twenty":-2.131147,"median":-1.799883,"eighty":-0.456871,"marketCap":64042868},{"date":"2022-07-01","current":-0.119492,"twenty":-2.117036,"median":-1.779206,"eighty":-0.404522,"marketCap":65078854},{"date":"2022-07-08","current":-0.178553,"twenty":-2.114885,"median":-1.775229,"eighty":-0.374437,"marketCap":97359285},{"date":"2022-07-15","current":-0.16618,"twenty":-2.112791,"median":-1.757551,"eighty":-0.311835,"marketCap":89754194},{"date":"2022-07-22","current":-0.126228,"twenty":-2.104622,"median":-1.730681,"eighty":-0.172576,"marketCap":68233904},{"date":"2022-07-29","current":-0.050085,"twenty":-2.094065,"median":-1.696083,"eighty":-0.163245,"marketCap":27100490},{"date":"2022-08-05","current":-0.080486,"twenty":-2.092997,"median":-1.661783,"eighty":-0.147283,"marketCap":43440839},{"date":"2022-08-12","current":-0.078297,"twenty":-2.090283,"median":-1.647621,"eighty":-0.137047,"marketCap":42381307},{"date":"2022-08-19","current":-0.057132,"twenty":-2.086906,"median":-1.419538,"eighty":-0.133244,"marketCap":30585172},{"date":"2022-08-26","current":-0.055552,"twenty":-2.08212,"median":-1.330192,"eighty":-0.127899,"marketCap":29502095},{"date":"2022-09-02","current":-0.049858,"twenty":-2.078456,"median":-1.292716,"eighty":-0.126164,"marketCap":26370590},{"date":"2022-09-09","current":-0.05116,"twenty":-2.075575,"median":-1.270969,"eighty":-0.12294,"marketCap":26959219},{"date":"2022-09-16","current":-0.048796,"twenty":-2.065194,"median":-1.255215,"eighty":-0.118547,"marketCap":25475874},{"date":"2022-09-23","current":-0.039638,"twenty":-2.063353,"median":-1.222255,"eighty":-0.116313,"marketCap":20295934},{"date":"2022-09-30","current":-0.039015,"twenty":-2.060974,"median":-1.20685,"eighty":-0.110557,"marketCap":20013392},{"date":"2022-10-07","current":-0.046815,"twenty":-2.059361,"median":-1.202242,"eighty":-0.107298,"marketCap":24016075},{"date":"2022-10-14","current":-0.028297,"twenty":-2.053383,"median":-1.161027,"eighty":-0.103114,"marketCap":14362548},{"date":"2022-10-21","current":-0.039236,"twenty":-2.053249,"median":-1.093833,"eighty":-0.097648,"marketCap":19777925},{"date":"2022-10-28","current":-0.025268,"twenty":-2.052577,"median":-0.866249,"eighty":-0.080655,"marketCap":12714380},{"date":"2022-11-04","current":-0.025026,"twenty":-2.047365,"median":-0.807298,"eighty":-0.076479,"marketCap":12714380},{"date":"2022-11-11","current":-0.025067,"twenty":-2.036617,"median":-0.802612,"eighty":-0.070361,"marketCap":12871348},{"date":"2022-11-18","current":-0.02472,"twenty":-2.033895,"median":-0.792119,"eighty":-0.067938,"marketCap":13365796},{"date":"2022-11-25","current":-0.024416,"twenty":-2.033597,"median":-0.773724,"eighty":-0.058896,"marketCap":13106799},{"date":"2022-12-02","current":-0.02261,"twenty":-2.0308,"median":-0.678708,"eighty":-0.055552,"marketCap":12400445},{"date":"2022-12-09","current":-0.033064,"twenty":-2.028961,"median":-0.654366,"eighty":-0.053501,"marketCap":18296935},{"date":"2022-12-16","current":-0.033686,"twenty":-2.028804,"median":-0.624845,"eighty":-0.052591,"marketCap":18600667},{"date":"2022-12-23","current":-0.028061,"twenty":-2.024208,"median":-0.603653,"eighty":-0.05116,"marketCap":15461314},{"date":"2022-12-30","current":-0.033224,"twenty":-2.018429,"median":-0.598643,"eighty":-0.05004,"marketCap":13976173},{"date":"2023-01-06","current":-0.035525,"twenty":-2.016647,"median":-0.576755,"eighty":-0.048778,"marketCap":15075423},{"date":"2023-01-13","current":-0.038857,"twenty":-2.011494,"median":-0.548181,"eighty":-0.043844,"marketCap":16802815},{"date":"2023-01-20","current":-0.036341,"twenty":-2.006489,"median":-0.524812,"eighty":-0.043618,"marketCap":15546530},{"date":"2023-01-27","current":-0.037268,"twenty":-2.002325,"median":-0.488901,"eighty":-0.041046,"marketCap":15939119},{"date":"2023-02-03","current":-0.032209,"twenty":-1.988961,"median":-0.437673,"eighty":-0.039418,"marketCap":13819138},{"date":"2023-02-10","current":-0.032054,"twenty":-1.969539,"median":-0.405847,"eighty":-0.038855,"marketCap":13662102},{"date":"2023-02-17","current":-0.033081,"twenty":-1.962196,"median":-0.385085,"eighty":-0.037617,"marketCap":13976173},{"date":"2023-02-24","current":-0.031059,"twenty":-1.956322,"median":-0.366417,"eighty":-0.036834,"marketCap":12955441},{"date":"2023-03-03","current":-0.030277,"twenty":-1.949443,"median":-0.321666,"eighty":-0.035859,"marketCap":12719888},{"date":"2023-03-10","current":-0.03035,"twenty":-1.944681,"median":-0.205389,"eighty":-0.035042,"marketCap":12719888},{"date":"2023-03-17","current":-0.024225,"twenty":-1.940658,"median":-0.168591,"eighty":-0.034739,"marketCap":10207317},{"date":"2023-03-24","current":-0.023789,"twenty":-1.936956,"median":-0.164967,"eighty":-0.033773,"marketCap":10050282},{"date":"2023-03-31","current":-0.023609,"twenty":-1.928998,"median":-0.154441,"eighty":-0.033604,"marketCap":9971764},{"date":"2023-04-06","current":-0.021583,"twenty":-1.928151,"median":-0.149132,"eighty":-0.033224,"marketCap":9108068},{"date":"2023-04-14","current":-0.021102,"twenty":-1.927796,"median":-0.139109,"eighty":-0.032326,"marketCap":8911773},{"date":"2023-04-21","current":-0.020645,"twenty":-1.927008,"median":-0.136903,"eighty":-0.032054,"marketCap":8715479},{"date":"2023-04-28","current":-0.018737,"twenty":-1.926255,"median":-0.133541,"eighty":-0.031127,"marketCap":7851783},{"date":"2023-05-05","current":-0.012233,"twenty":-1.92564,"median":-0.132085,"eighty":-0.030656,"marketCap":5136636},{"date":"2023-05-12","current":-0.010151,"twenty":-1.924934,"median":-0.129315,"eighty":-0.030422,"marketCap":4239962},{"date":"2023-05-17","current":-0.015525,"twenty":-1.924699,"median":-0.12872,"eighty":-0.030394,"marketCap":6438462},{"date":"2023-05-24","current":-0.01241,"twenty":-1.923847,"median":-0.127351,"eighty":-0.030312,"marketCap":5104444},{"date":"2023-06-06","current":-0.011294,"twenty":-1.923229,"median":-0.127082,"eighty":-0.030287,"marketCap":4601144},{"date":"2023-06-23","current":-0.01166,"twenty":-1.921377,"median":-0.126789,"eighty":-0.029623,"marketCap":4711077},{"date":"2023-06-30","current":-0.010029,"twenty":-1.921221,"median":-0.126228,"eighty":-0.029556,"marketCap":4013046},{"date":"2023-07-07","current":-0.010029,"twenty":-1.919653,"median":-0.124609,"eighty":-0.028693,"marketCap":4011475},{"date":"2023-07-12","current":-0.009839,"twenty":-1.918319,"median":-0.124133,"eighty":-0.028553,"marketCap":3984779},{"date":"2023-07-21","current":-0.008368,"twenty":-1.91375,"median":-0.121995,"eighty":-0.028166,"marketCap":3384118},{"date":"2023-07-28","current":-0.009713,"twenty":-1.912037,"median":-0.11887,"eighty":-0.026558,"marketCap":3929825},{"date":"2023-08-04","current":-0.009982,"twenty":-1.909343,"median":-0.117384,"eighty":-0.025968,"marketCap":4042883},{"date":"2023-08-11","current":-0.063124,"twenty":-1.906409,"median":-0.115148,"eighty":-0.025993,"marketCap":13214071},{"date":"2023-08-18","current":-0.056265,"twenty":-1.905085,"median":-0.111944,"eighty":-0.026014,"marketCap":11659474},{"date":"2023-08-25","current":-0.040431,"twenty":-1.904385,"median":-0.109246,"eighty":-0.026167,"marketCap":8394821},{"date":"2023-09-01","current":-0.039579,"twenty":-1.903063,"median":-0.107257,"eighty":-0.026558,"marketCap":8239361},{"date":"2023-09-08","current":-0.030164,"twenty":-1.902079,"median":-0.104191,"eighty":-0.026916,"marketCap":6218386},{"date":"2023-09-15","current":-0.04193,"twenty":-1.899271,"median":-0.102845,"eighty":-0.027374,"marketCap":8705740},{"date":"2023-09-22","current":-0.034966,"twenty":-1.893257,"median":-0.099135,"eighty":-0.02807,"marketCap":7228874},{"date":"2023-09-29","current":-0.034571,"twenty":-1.892684,"median":-0.093499,"eighty":-0.028136,"marketCap":7154253},{"date":"2023-10-06","current":-0.031555,"twenty":-1.890304,"median":-0.081333,"eighty":-0.028263,"marketCap":6529305},{"date":"2023-10-13","current":-0.030714,"twenty":-1.88724,"median":-0.07903,"eighty":-0.028305,"marketCap":6356745},{"date":"2023-10-20","current":-0.027124,"twenty":-1.884852,"median":-0.078297,"eighty":-0.028205,"marketCap":5602766},{"date":"2023-10-27","current":-0.028607,"twenty":-1.883153,"median":-0.076024,"eighty":-0.028158,"marketCap":5907467},{"date":"2023-11-03","current":-0.03162,"twenty":-1.875108,"median":-0.073429,"eighty":-0.02823,"marketCap":6529305},{"date":"2023-11-10","current":-0.028477,"twenty":-1.870637,"median":-0.069813,"eighty":-0.02823,"marketCap":5907467},{"date":"2023-11-16","current":-0.03539,"twenty":-1.865237,"median":-0.069098,"eighty":-0.028106,"marketCap":7384333}],"updateTime":1743641290319}}}